We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look ...

Type a few symbols and Take a Trial. The signals for these will appear immediately on your My Stocks Page; add more too.

Michael Chi, Chief Commercial Officer of Hims & Hers Health, Inc. (NYSE:HIMS), reported a significant transaction involving ...

Dakota Wealth Management cut its position in Hims & Hers Health, Inc. (NYSE:HIMS – Free Report) by 13.4% during the fourth ...

Citigroup has recently reduced Hims & Hers Health Inc (HIMS) stock to Sell rating, as announced on January 10, 2025, according to Finviz. Earlier, on January 7, 2025, BTIG Research had initiated the ...

Hims & Hers Health ( HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth ...

Discover why Hims & Hers Health is a top telehealth leader with impressive growth potential and a promising future for ...

Financial writer highlights undervalued Hims & Hers Health with impressive growth potential and innovative product launches, ...

In recent trading, Hims & Hers Health Inc (HIMS) stock price has shown some volatility, fluctuating 9.60% over the last five trades and -10.88% over the past 30 trades. This represents a notable shift ...

Hims & Hers Health has donated $1 million to President-elect Donald Trump's inauguration fund, CNBC confirmed Tuesday. The company is the latest in a string of tech organizations that have tried to ...

Hims & Hers sells compounded GLP-1 agonists, which have become its identity in the eyes of the market. The company is poised to grow, even if it must shut down its compounded GLP-1 agonist business.